ErythroSight
Biotechnology Research • 
Canberra, Australian Capital Territory, Australia • 1-10 Employees
Company overview
| Headquarters | 131 Garran Rd, Acton, Australian Capital Territory 2601, AU |
| Phone number | +61261258559 |
| Website | |
| NAICS | 541714 |
| Founded | 2023 |
| Employees | 1-10 |
Key Contact at ErythroSight
Adrian Cioanca
Chief Technology Officer
About ErythroSight
At ErythroSight (a spinout being incubated at ANU and Clear Vision Research), we are developing next-generation therapeutics for the treatment of retinal- and neuro-degenerations. Using Red Blood Cell Derived Extracellular Vesicles (RBC-EVs), we are developing a safe, inexpensive and personalised blood-derived product to treat Age-related Macular Degeneration (AMD), the number one cause of irreversible blindness in the developed world.
ErythroSight revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
ErythroSight has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
ErythroSight has never raised funding before.
ErythroSight Tech Stack
Discover the technologies and tools that power ErythroSight's digital infrastructure, from frameworks to analytics platforms.
Appointment scheduling
Blogs
Miscellaneous
Security
JavaScript frameworks
IaaS
CDN
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
